Comments on "Randomized, two-arm, non-comparative phase 2 study of olaparib plus cediranib or durvalumab in HRR-mutated, platinum-resistant ovarian cancer: A substudy of KGOG 3045"

Int J Cancer. 2024 Feb 15;154(4):762-763. doi: 10.1002/ijc.34785. Epub 2023 Oct 31.

Authors

Dongyue Xia¹, Xueyuan Xu^{2

3}, Pei Du²

Affiliations

¹ Department of Gynaecology and Obstetrics, Taizhou Central Hospital (Taizhou University Hospital), Taizhou, China.
² Department of Gynaecology and Obstetrics, Guangzhou Panyu Central Hospital, Guangzhou, Guangdong, China.
³ South China Normal University, Guangzhou, China.

PMID: 37907806
DOI: 10.1002/ijc.34785

No abstract available

Publication types

Letter

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / adverse effects
Carcinoma, Ovarian Epithelial
Female
Humans
Neoplasm Recurrence, Local / drug therapy
Ovarian Neoplasms* / drug therapy
Ovarian Neoplasms* / genetics
Phthalazines / adverse effects

Substances

cediranib
durvalumab
olaparib
Phthalazines

Grants and funding